Trial Profile
A randomized, open-label, two way self-crossover study of gimeracil/oteracil/tegafur in chinese cancer patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Dec 2015
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- 01 Dec 2015 New trial record